BeOne Medicines Clinical Trials: 185 Led Studies

Archive historyOct 2022 to Sept 2026

132 recorded changes across BeOne Medicines trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 40 of these trials. One is shown below.

Enrollment changeEnrollment grew to 58 from 34NCT07005713 · recorded 15 Sept 2026

Track to read them

+128 more recorded changes · Track a drug to see every change the night it lands

Track zanubrutinib

Most active programmes

The drugs appearing most often across BeOne Medicines's recently active trials. Comparator arms are excluded.

Tislelizumab35 trials
Zanubrutinib20 trials
Sonrotoclax11 trials
BGB-433957 trials
Cisplatin7 trials
Obinutuzumab7 trials

Upcoming readouts

Next primary completion dates among BeOne Medicines's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Nov 2026Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumor…Phase 2
Oct 2027A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous In…Phase 3
Apr 2028A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutini…Phase 3
May 2028CaDAnCe-302: A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chron…Phase 3
Aug 2028A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Pl…Phase 3
Apr 2029KANDELA-302: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic …Phase 3

Top therapeutic areas

Conditions studied most often across BeOne Medicines's recently active trials.

Advanced Solid Tumor20 trials
Chronic Lymphocytic Leukemia10 trials
Small Lymphocytic Lymphoma7 trials
Mantle Cell Lymphoma6 trials
Metastatic Solid Tumor5 trials
Marginal Zone Lymphoma5 trials

BeOne Medicines trials

The 50 most significant of BeOne Medicines's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaNCT05952037Sonrotoclax	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	114 est.	22 Sept 2026
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsNCT07628881Sonrotoclax Tablet for Oral Suspension	Phase 1	Not yet scored	OngoingRecruiting	12 est.	27 Sept 2026
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsNCT07590102BGB-58067	Phase 1	Locked · track to reveal	OngoingRecruiting	30 est.	30 Sept 2026
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsNCT03736889Tislelizumab (BGB-A317)	Phase 2	Locked · track to reveal	OngoingRecruiting	200 est.	Nov 2026
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaNCT04973605Sonrotoclax	Phase 1	Locked · track to reveal	OngoingRecruiting	246 est.	Nov 2026
CaDAnCe-101A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesNCT05006716Tacabrutideg	Phase 1	Locked · track to reveal	OngoingRecruiting	645 est.	Nov 2026
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaNCT06637501Sonrotoclax	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	94 est.	Nov 2026
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395NCT07820891BGB-43395	Phase 1	Not yet scored	OngoingNot yet recruiting	24 est.	22 Nov 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy ParticipantsNCT07005713Tacabrutideg	Phase 1	Locked · track to reveal	OngoingRecruiting	58 est.	30 Nov 2026
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaNCT05640102Zanubrutinib	—	Locked · track to reveal	OngoingRecruiting	111 est.	Dec 2026
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid TumorsNCT06625593BG-C137	Phase 1	Locked · track to reveal	OngoingRecruiting	168 est.	31 Dec 2026
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibNCT04170283Zanubrutinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	955 est.	31 Dec 2026
MANGROVEA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationNCT04002297zanubrutinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	510 est.	Mar 2027
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsNCT06427941BGB-B2033	Phase 1	Locked · track to reveal	OngoingRecruiting	630 est.	31 Mar 2027
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesNCT04277637Sonrotoclax	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	437 est.	31 May 2027
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaNCT03967977Tislelizumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	420 est.	30 Jun 2027
A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsNCT07712640BGB-58067 Tablet (F-01 Formulation)	Phase 1	Not yet scored	OngoingRecruiting	32 est.	1 Jul 2027
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932BGB-21447	Phase 1	Locked · track to reveal	OngoingRecruiting	120 est.	30 Jul 2027
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid TumorsNCT06233942BG-C9074	Phase 1	Locked · track to reveal	OngoingRecruiting	308 est.	28 Sept 2027
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid TumorsNCT06589596BGB-58067	Phase 1	Locked · track to reveal	OngoingRecruiting	525 est.	30 Sept 2027
ALMONDA Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyNCT05707377Zanubrutinib	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	178 est.	Oct 2027
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07043400Subcutaneous Tislelizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	351 est.	30 Oct 2027
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid TumorsNCT07181681BG-C0902	Phase 1	Locked · track to reveal	OngoingRecruiting	63 est.	1 Nov 2027
TITANSA Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)NCT07652736Tislelizumab	—	Not yet scored	OngoingRecruiting	440 est.	15 Nov 2027
A Study of BG-C477 in Participants With Advanced Solid TumorsNCT06596473BG-C477	Phase 1	Locked · track to reveal	OngoingRecruiting	310 est.	31 Dec 2027
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCNCT07733180Tislelizumab	Phase 2	Not yet scored	OngoingNot yet recruiting	30 est.	28 Feb 2028
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT06973187Tacabrutideg	Phase 3	Locked · track to reveal	OngoingRecruiting	500 est.	17 Apr 2028
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid TumorsNCT06803680BGB-B455	Phase 1	Locked · track to reveal	OngoingRecruiting	90 est.	29 Apr 2028
CaDAnCe-302A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsNCT06846671Tacabrutideg	Phase 3	Locked · track to reveal	OngoingRecruiting	250 est.	15 May 2028
MAHOGANYA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaNCT05100862Zanubrutinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	799 est.	Jul 2028
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin DiseasesNCT07412691BG-A3004	Phase 1	Locked · track to reveal	OngoingRecruiting	98 est.	8 Aug 2028
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)NCT06742996Sonrotoclax	Phase 3	Locked · track to reveal	OngoingRecruiting	300 est.	31 Aug 2028
A Study of BGB-11417 in Participants With Myeloid MalignanciesNCT04771130BGB-11417	Phase 1	Locked · track to reveal	OngoingRecruiting	260 est.	31 Aug 2028
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid MalignanciesNCT07619287BG-75202	Phase 1	Not yet scored	OngoingRecruiting	118 est.	30 Sept 2028
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid TumorsNCT06598800Drug: BG-T187	Phase 1	Locked · track to reveal	OngoingRecruiting	153 est.	30 Sept 2028
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) MutationsNCT07746141BG-85738	Phase 1	Locked · track to reveal	OngoingRecruiting	100 est.	30 Sept 2028
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaNCT07169331Zanubrutinib	Phase 4	Locked · track to reveal	OngoingActive, not recruiting	16 est.	31 Oct 2028
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsNCT07226349BG-75098	Phase 1	Locked · track to reveal	OngoingRecruiting	105 est.	1 Nov 2028
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesNCT06634589Tacabrutideg	Phase 1	Locked · track to reveal	OngoingRecruiting	80 est.	2 Dec 2028
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderNCT05294731BGB-16673	Phase 1	Locked · track to reveal	OngoingRecruiting	146 est.	31 Jan 2029
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid TumorsNCT05981703BGB-26808	Phase 1	Locked · track to reveal	OngoingRecruiting	337 est.	28 Feb 2029
KANDELA-302BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641BGB-43395	Phase 3	Locked · track to reveal	OngoingRecruiting	1,056 est.	Apr 2029
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid TumorsNCT07414836BG-C0979	Phase 1	Locked · track to reveal	OngoingRecruiting	84 est.	30 Apr 2029
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)NCT06943872Sonrotoclax	Phase 3	Locked · track to reveal	OngoingRecruiting	630 est.	30 Sept 2029
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267BG-75202	Phase 1	Locked · track to reveal	OngoingRecruiting	86 est.	30 Sept 2029
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.NCT06697184Sonrotoclax	Phase 1	Locked · track to reveal	OngoingRecruiting	258 est.	30 Nov 2029
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal CancersNCT07811271BG-C9074	Phase 3	Not yet scored	OngoingNot yet recruiting	600 est.	30 Nov 2029
CaDAnCe-303A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsNCT06970743BGB-16673	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	153 est.	30 Nov 2029
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283BGB-43395	Phase 1	Locked · track to reveal	OngoingRecruiting	433 est.	Dec 2029
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNCT07770698sonrotoclax	Phase 1	Not yet scored	OngoingNot yet recruiting	30 est.	30 Apr 2030

Track zanubrutinib

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Phase 2Active, not recruitingNCT05952037 ↗

Primary completion: Sept 2026; estimated
Enrollment: 114; estimated
Start: Oct 2023; BeOne Medicines

Conditions

Waldenstrom Macroglobulinemia
Waldenstrom's Macroglobulinemia Recurrent
Waldenstrom's Macroglobulinemia Refractory

Interventions

Sonrotoclax
Zanubrutinib

Brief summary

This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Feb 2026

Completion date move · 2

Enrollment change · 2

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants

Phase 1RecruitingNCT07590102 ↗

Primary completion: Sept 2026; estimated
Enrollment: 30; estimated
Start: Jun 2026; BeOne Medicines

Conditions

Healthy Volunteers

Interventions

BGB-58067
Phenytoin
Itraconazole

Brief summary

This study is being done to understand how the body processes the study drug (BGB-58067) when it is taken together with other medicines. BGB-58067 is mainly broken down in the body by a liver enzyme called CYP3A. Some medicines can affect how this enzyme works. For example, certain medicines can increase the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 21 Jul 2026

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase 2RecruitingNCT03736889 ↗

Primary completion: Nov 2026; estimated
Enrollment: 200; estimated
Start: Sept 2018; BeiGene

Conditions

MSI-H/dMMR Solid Tumors

Interventions

Tislelizumab (BGB-A317)

Brief summary

In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2023

Enrollment change · 1

Completion date move · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1RecruitingNCT04973605 ↗

Primary completion: Nov 2026; estimated
Enrollment: 246; estimated
Start: Sept 2021; BeOne Medicines

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

Sonrotoclax
Dexamethasone
Carfilzomib
Daratumumab
Pomalidomide

Brief summary

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jul 2025

Enrollment change · 1

Completion date move · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

CaDAnCe-101: A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Phase 1RecruitingNCT05006716 ↗

Primary completion: Nov 2026; estimated
Enrollment: 645; estimated
Start: Sept 2021; BeOne Medicines

Conditions

B-cell Malignancy
Marginal Zone Lymphoma
Follicular Lymphoma
Non-Hodgkin Lymphoma
Waldenström Macroglobulinemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Mantle Cell Lymphoma

Interventions

Tacabrutideg

Brief summary

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 22 Aug 2026

Completion date move · 4

Enrollment change · 4

Registry change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2Active, not recruitingNCT06637501 ↗

Primary completion: Nov 2026; estimated
Enrollment: 94; estimated
Start: Nov 2024; BeOne Medicines

Conditions

Chronic Lymphocytic Leukemia

Interventions

Sonrotoclax
Zanubrutinib

Brief summary

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Completion date move · 1

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

Phase 1RecruitingNCT07005713 ↗

Primary completion: Nov 2026; estimated
Enrollment: 58; estimated
Start: Jul 2025; BeOne Medicines

Conditions

Chronic Spontaneous Urticaria

Interventions

Tacabrutideg
Placebo

Brief summary

This is a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of tacabrutideg in adults with chronic spontaneous urticaria (CSU) and in healthy participants.

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 15 Sept 2026

Status change · 4

Completion date move · 3

Enrollment change · 2

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Phase 1RecruitingNCT06625593 ↗

Primary completion: Dec 2026; estimated
Enrollment: 168; estimated
Start: Dec 2024; BeOne Medicines

Conditions

Advanced Solid Tumor

Interventions

BG-C137
Anticancer Agents

Brief summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

Phase 3Active, not recruitingNCT04170283 ↗

Primary completion: Dec 2026; estimated
Enrollment: 955; estimated
Start: Jan 2020; BeOne Medicines

Conditions

B-cell Malignancies

Interventions

Zanubrutinib
Tislelizumab

Brief summary

The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have taken part in long-term follow-up…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Nov 2025

Status change · 3

Enrollment change · 1

Completion date move · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

MANGROVE: A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Phase 3Active, not recruitingNCT04002297 ↗

Primary completion: Mar 2027; estimated
Enrollment: 510; estimated
Start: Aug 2019; BeOne Medicines

Conditions

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Interventions

zanubrutinib
bendamustine
rituximab

Brief summary

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 14 Jul 2026

Completion date move · 1

Status change · 1

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Phase 1RecruitingNCT06427941 ↗

Primary completion: Mar 2027; estimated
Enrollment: 630; estimated
Start: Jul 2024; BeOne Medicines

Conditions

Metastatic Hepatocellular Carcinoma
Local Advanced Hepatocellular Carcinoma
Alpha-fetoprotein (AFP)-Producing Gastric Cancer
Extragonadal Yolk Sac Tumors
Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Interventions

BGB-B2033
Tislelizumab
Bevacizumab

Brief summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic hepatocellular carcinoma (HCC),…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 8 Sept 2026

Completion date move · 2

Enrollment change · 2

Registry change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Phase 1Active, not recruitingNCT04277637 ↗

Primary completion: May 2027; estimated
Enrollment: 437; estimated
Start: Mar 2020; BeOne Medicines

Conditions

Mature B-Cell Malignancies

Interventions

Sonrotoclax
Zanubrutinib
Obinutuzumab

Brief summary

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Apr 2026

Completion date move · 3

Enrollment change · 2

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3Active, not recruitingNCT03967977 ↗

Primary completion: Jun 2027; estimated
Enrollment: 420; estimated
Start: May 2019; BeiGene

Conditions

Urothelial Carcinoma

Interventions

Tislelizumab
Placebo
Cisplatin
Gemcitabine Hydrochloride
Carboplatin

Brief summary

This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or carboplatin + gemcitabine in approximately 420 participants with locally advanced or…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Phase 1RecruitingNCT06756932 ↗

Primary completion: Jul 2027; estimated
Enrollment: 120; estimated
Start: Feb 2025; BeOne Medicines

Conditions

Hormone-receptor-positive Breast Cancer
HER2-negative Breast Cancer
Metastatic Breast Cancer

Interventions

BGB-21447
Fulvestrant
BGB-43395

Brief summary

This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Nov 2025

Completion date move · 1

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1RecruitingNCT06233942 ↗

Primary completion: Sept 2027; estimated
Enrollment: 308; estimated
Start: Apr 2024; BeOne Medicines

Conditions

Advanced Solid Tumor

Interventions

BG-C9074
Tislelizumab
Bevacizumab

Brief summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Dec 2025

Enrollment change · 2

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Phase 1RecruitingNCT06589596 ↗

Primary completion: Sept 2027; estimated
Enrollment: 525; estimated
Start: Jan 2025; BeOne Medicines

Conditions

Advanced Solid Tumor

Interventions

BGB-58067
BG-89894
Standard of Care Therapy

Brief summary

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard of care therapy in…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jun 2026

Completion date move · 3

Enrollment change · 2

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

ALMOND: A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Phase 2Active, not recruitingNCT05707377 ↗

Primary completion: Oct 2027; estimated
Enrollment: 178; estimated
Start: Apr 2023; BeOne Medicines

Conditions

Primary Membranous Nephropathy

Interventions

Zanubrutinib
Tacrolimus

Brief summary

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 15 Jul 2026

Completion date move · 3

Status change · 2

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3RecruitingNCT07043400 ↗

Primary completion: Oct 2027; estimated
Enrollment: 351; estimated
Start: Aug 2025; BeOne Medicines

Conditions

Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

Subcutaneous Tislelizumab
Intravenous Tislelizumab
Cisplatin
Leucovorin
5-fluorouracil (5-FU)
Oxaliplatin
Capecitabine

Brief summary

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Oct 2025

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Phase 1RecruitingNCT07181681 ↗

Primary completion: Nov 2027; estimated
Enrollment: 63; estimated
Start: Nov 2025; BeOne Medicines

Conditions

Solid Tumors
Advanced Solid Tumor

Interventions

BG-C0902

Brief summary

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

Phase 2Not yet recruitingNCT07733180 ↗

Primary completion: Feb 2028; estimated
Enrollment: 30; estimated
Start: Aug 2026; BeOne Medicines

Conditions

Advanced Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma

Interventions

Tislelizumab
Oxaliplatin
Leucovorin
5-fluorouracil (5-FU)

Brief summary

The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line treatment in Japanese participants with previously untreated, unresectable locally advanced,…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3RecruitingNCT06973187 ↗

Primary completion: Apr 2028; estimated
Enrollment: 500; estimated
Start: Sept 2025; BeOne Medicines

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

Tacabrutideg
Pirtobrutinib

Brief summary

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

Phase 1RecruitingNCT06803680 ↗

Primary completion: Apr 2028; estimated
Enrollment: 90; estimated
Start: Mar 2025; BeOne Medicines

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor

Interventions

BGB-B455
Chemotherapy

Brief summary

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Completion date move · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

CaDAnCe-302: A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Phase 3RecruitingNCT06846671 ↗

Primary completion: May 2028; estimated
Enrollment: 250; estimated
Start: Apr 2025; BeOne Medicines

Conditions

CLL
Chronic Lymphocytic Leukemia

Interventions

Tacabrutideg
Bendamustine
Idelalisib
Rituximab
Venetoclax

Brief summary

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jul 2025

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

MAHOGANY: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Phase 3Active, not recruitingNCT05100862 ↗

Primary completion: Jul 2028; estimated
Enrollment: 799; estimated
Start: Mar 2022; BeOne Medicines

Conditions

Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma

Interventions

Zanubrutinib
Rituximab
Lenalidomide
Obinutuzumab

Brief summary

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 16 Jul 2026

Completion date move · 3

Enrollment change · 2

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Phase 3RecruitingNCT06742996 ↗

Primary completion: Aug 2028; estimated
Enrollment: 300; estimated
Start: Mar 2025; BeOne Medicines

Conditions

Mantle Cell Lymphoma
B Cell Lymphoma

Interventions

Sonrotoclax
Zanubrutinib
Placebo

Brief summary

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2026

Completion date move · 1

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study of BGB-11417 in Participants With Myeloid Malignancies

Phase 1RecruitingNCT04771130 ↗

Primary completion: Aug 2028; estimated
Enrollment: 260; estimated
Start: May 2021; BeOne Medicines

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm

Interventions

BGB-11417
Azacitidine
Posaconazole
BGB-11417
BGB-11417

Brief summary

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 14 Sept 2026

Completion date move · 3

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Phase 1RecruitingNCT06598800 ↗

Primary completion: Sept 2028; estimated
Enrollment: 153; estimated
Start: Oct 2024; BeOne Medicines

Conditions

Advanced Solid Tumor

Interventions

Drug: BG-T187
Other Therapeutic Agents

Brief summary

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Status change · 3

Enrollment change · 1

Completion date move · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

Phase 4Active, not recruitingNCT07169331 ↗

Primary completion: Oct 2028; estimated
Enrollment: 16; estimated
Start: Oct 2025; BeiGene

Conditions

Waldenström's Macroglobulinemia

Interventions

Zanubrutinib

Brief summary

The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 11 Aug 2026

Status change · 2

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1RecruitingNCT06634589 ↗

Primary completion: Dec 2028; estimated
Enrollment: 80; estimated
Start: Nov 2024; BeOne Medicines

Conditions

B-cell Malignancy
Relapsed Cancer
Refractory Cancer
B-cell Lymphoma

Interventions

Tacabrutideg
Sonrotoclax
Zanubrutinib
Mosunetuzumab
Glofitamab
Obinutuzumab

Brief summary

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies.…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 21 Aug 2026

Registry change · 1

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase 1RecruitingNCT05294731 ↗

Primary completion: Jan 2029; estimated
Enrollment: 146; estimated
Start: May 2022; BeiGene

Conditions

B-cell Malignancy
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Follicular Lymphoma
DLBCL Unclassifiable

Interventions

BGB-16673

Brief summary

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Completion date move · 2

Enrollment change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1RecruitingNCT05981703 ↗

Primary completion: Feb 2029; estimated
Enrollment: 337; estimated
Start: Sept 2023; BeOne Medicines

Conditions

Advanced Solid Tumor
Solid Tumor

Interventions

BGB-26808
Tislelizumab
Chemotherapy

Brief summary

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Sept 2026

Enrollment change · 3

Completion date move · 2

Registry change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

KANDELA-302: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3RecruitingNCT07492641 ↗

Primary completion: Apr 2029; estimated
Enrollment: 1,056; estimated
Start: May 2026; BeOne Medicines

Conditions

HR+/HER2- Breast Cancer

Interventions

BGB-43395
Letrozole
Abemaciclib
Palbociclib
Ribociclib

Brief summary

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase 3RecruitingNCT06943872 ↗

Primary completion: Sept 2029; estimated
Enrollment: 630; estimated
Start: Jun 2025; BeOne Medicines

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

Sonrotoclax
Obinutuzumab
Rituximab
Venetoclax

Brief summary

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Phase 1RecruitingNCT07222267 ↗

Primary completion: Sept 2029; estimated
Enrollment: 86; estimated
Start: Dec 2025; BeOne Medicines

Conditions

Breast Cancer
Advanced Solid Tumor

Interventions

BG-75202
CDK4 Inhibitor
Estrogen Receptor Antagonist
Aromatase Inhibitor

Brief summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2026

Completion date move · 1

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Phase 3Not yet recruitingNCT07811271 ↗

Primary completion: Nov 2029; estimated
Enrollment: 600; estimated
Start: Oct 2026; BeOne Medicines

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

BG-C9074
Bevacizumab

Brief summary

The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after firstline platinum-based chemotherapy plus bevacizumab.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Phase 3Active, not recruitingNCT06970743 ↗

Primary completion: Nov 2029; estimated
Enrollment: 153; estimated
Start: May 2025; BeOne Medicines

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

BGB-16673
Bendamustine
Rituximab
Methylprednisolone
Chlorambucil
Obinutuzumab

Brief summary

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 28 Jul 2026

Enrollment change · 1

Status change · 1

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1RecruitingNCT06120283 ↗

Primary completion: Dec 2029; estimated
Enrollment: 433; estimated
Start: Dec 2023; BeOne Medicines

Conditions

Advanced Solid Tumor
Advanced Breast Cancer
Metastatic Breast Cancer
Hormone-receptor-positive Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Hormone Receptor Positive Malignant Neoplasm of Breast
HER2-negative Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer

Interventions

BGB-43395
Fulvestrant
Letrozole
Elacestrant
Anti-Diarrheal Agent

Brief summary

This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 28 Aug 2026

Completion date move · 3

Enrollment change · 2

Track BeOne Medicines drugs to see every change the night it lands.

Track zanubrutinib

A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

Phase 1Not yet recruitingNCT07770698 ↗

Primary completion: Apr 2030; estimated
Enrollment: 30; estimated
Start: Oct 2026; BeOne Medicines

Conditions

Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
B-cell Acute Lymphoblastic Leukemia
Pediatric Cancer
Pediatric ALL, Relapsed
Pediatric ALL
Pediatric ALL, B Cell
Acute Myeloid Leukemia

Interventions

sonrotoclax
Azacitidine
Inotuzumab ozogamicin
Dexamethasone

Brief summary

The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment or has not responded to treatment. The study will also learn how the body processes…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.